Table 2 Number of post-study therapy lines and cross-overs

From: Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

Treatment

Patients (%)

Number of lines

 0

10

 1

21

 2

25

 3

21

 4

13

 5–11

10

 2 or more lines

69

Cross-overs a

 CP arm

68

 CD arm

43

  1. Abbreviations: CD=carboplatin-pegylated liposomal doxorubicin; CP=carboplatin-paclitaxel.
  2. aP<0.001 for comparison between arms.
Back to article page